Oribase Pharma

Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Institut Regional Du Cancer De Montpellier-Val D'aurelle

Inserm

Université De Montpellier I

Bénédicte Fauvel

Gwénaël Cheve

Cédric Bories

Abdelaziz Yasri

Bénédicte Dayde-Cazals

Christel Larbouret

Bruno Robert

Andre Pelegrin

André Pelegrin

Thierry Chardes

Christian Larroque

Gwenael Cheve

Aziz Yasri

Wilhem Leconet

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders. 

Azaindole derivatives as multi kinase inhibitors

Azaindole derivatives as inhibitors of protein kinases

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.

Anti-Axl antibodies and uses thereof

Protein kinase inhibitors

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.

Growing community of inventors

Montpellier, France

Bénédicte Fauvel